IFAM
NKTR icon

Institutional & Family Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Institutional & Family Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-2
Closed -$1K – 864
2018
Q2 		$1K Hold
2
– – ﹤0.01% 803
2018
Q1 		$3K Buy
+2
New +$2.58K ﹤0.01% 675

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Institutional & Family Asset Management's NKTR Position: Q3 2018 in Review

Institutional & Family Asset Management sold out of Nektar Therapeutics (NKTR) in Q3 2018, closing a stake of 2 shares — an estimated $1K sold.

Institutional & Family Asset Management first reported a position in NKTR in Q1 2018 and held it in 2 quarters. The position peaked at $3K in Q1 2018. 389 funds tracked by Wall St. Rank hold NKTR as of Q3 2018.

  • Institutional & Family Asset Management reported no remaining Nektar Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Institutional & Family Asset Management sold 2 Nektar Therapeutics shares in Q3 2018, an estimated $1K.
  • Institutional & Family Asset Management first reported a position in Nektar Therapeutics in Q1 2018 and held it in 2 quarters.
  • Institutional & Family Asset Management's Nektar Therapeutics position peaked at $3K in Q1 2018.
  • 389 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2018.

Based on Institutional & Family Asset Management's 13F filing for Q3 2018, filed 13 Nov 2018.